We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

By LabMedica International staff writers
Posted on 14 Dec 2014
Print article
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).
An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them.

Investigators at the University of California, San Francisco (USA), St. Jude Children’s Research Hospital (Memphis, TN, USA), and other institutions treated a mouse model of malaria with the candidate drug compound (+)-SJ733. This drug was developed from a dihydroisoquinolone chemical series that had been identified in a phenotypic high-throughput screen. The compound is thought to inhibit the enzyme Plasmodium falciparum Ca2+-ATPase (ATP4), which is a cation-transporting ATPase responsible for maintaining low intracellular sodium ion levels in the parasite.

Results published in the December 1, 2014, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America revealed that in the mouse model, a single dose of (+)-SJ733 killed 80% of malaria parasites within 24 hours, and after 48 hours no parasites were detectable.

In vitro, the treatment of parasitized erythrocytes with (+)-SJ733 caused rapid disruption of sodium ion equilibrium in the parasite. This perturbation was followed by profound physical changes in the infected cells, including increased membrane rigidity and externalization of phosphatidylserine, consistent with eryptosis (erythrocyte suicide) or senescence.

The immune systems of the treated animals responded to these changes in infected erythrocytes by removing them using the same mechanism the body relies on to rid itself of aging red blood cells. Parasites that evolved resistance to (+)-SJ733 were defective in other ways and failed to transmit the disease.

Contributing author Dr. Joseph DeRisi, professor of biochemistry and biophysics at the University of California, San Francisco, said, "The data suggest that compounds targeting ATP4 induce physical changes in the infected red blood cells that allow the immune system or erythrocyte quality control mechanisms to recognize and rapidly eliminate infected cells. This rapid clearance response depends on the presence of both the parasite and the investigational drug. That is important because it leaves uninfected red blood cells, also known as erythrocytes, unharmed."

Further development of (+)-SJ733 and the requisite clinical trials will be conducted by a consortium that includes investigators at St. Jude Children’s Research Hospital, the Swiss-based non-profit organization Medicines for Malaria Venture (Geneva, Switzerland), and the Japanese pharmaceutical company Eisai (Tokyo, Japan).

Related Links:

University of California, San Francisco
St. Jude Children’s Research Hospital
Medicines for Malaria Venture



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.